Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals

A. Carletto, Americo Cicchetti, Silvia Coretti, Vito Moramarco, Matteo Ruggeri*

*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

2 Citazioni (Scopus)

Abstract

The aim of this paper is to provide an empirical framework based on a discrete-time Markov chain to assess the costs and benefits of Performance Based Agreements (PBAs) for the reimbursement of pharmaceuticals. We provide an empirical testing using a case study referring to a treatment recently approved for reimbursement in Italy. The implementation of this framework is challenging for the agencies dealing with pricing and reimbursement decisions given the uncertainty associated with the treatment effectiveness and safety. On the other hand, empirical evidence shows that the awareness of the expected costs associated with different reimbursement schemes is necessary to inform decision-makers.
Lingua originaleEnglish
pagine (da-a)89-101
Numero di pagine13
RivistaEurasian Business Review
Volume9
DOI
Stato di pubblicazionePubblicato - 2019

Keywords

  • Cost-benefit Analysis
  • Markov models
  • Performance Based Agreements
  • Pharmaceutical policy
  • Pricing and Reimbursement

Fingerprint

Entra nei temi di ricerca di 'Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals'. Insieme formano una fingerprint unica.

Cita questo